VTGN logo

VistaGen Therapeutics (VTGN) Cash From Financing

Annual CFF

$128.40 M
+$129.44 M+12434.49%

March 31, 2024

Summary

Performance

1-Year Change

+12434.49%

3-Year Change

+12.53%

5-Year Change

+636.95%

15-Year Change

+1184.79%

VTGN Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

88.33%
VTGN annual cash flow from financing activities is higher than 88.33% of companies in Healthcare sector

High & Low

All-time High

$128.40 M
VTGN annual cash flow from financing activities is currently at an all-time high

3-Year Low

-$1.04 M

Earnings dates

Last Annual Earnings Report Date

Mar 31, 2024
VTGN previous annual earnings announcement was published on Mar 31, 2024

Next Annual Earnings Report Date

N/A
VTGN next annual earnings announcement has not yet been scheduled

OtherVTGNcash flowmetrics:

Annual CFI

-$61.00 K
VTGN annual cash flow from investing activities is -$61.00 thousand

Annual CFO

-$25.81 M
VTGN annual cash flow from operations is -$25.81 million

Annual FCF

-$25.87 M
VTGN annual free cash flow is -$25.87 million

Annual CAPEX

$61.00 K
VTGN annual capital expenditures is $61.00 thousand

Quarterly CFF

$0.00
-$88.00 K-100.00%

September 30, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

0%

3-Year Change

0%

5-Year Change

0%

VTGN Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

45.69%
VTGN quarterly cash flow from financing activities is higher than 45.69% of companies in Healthcare sector

High & Low

All-time High

$94.07 M
VTGN quarterly cash flow from financing activities is currently -100.00% below its historical high of $94.07 million

3-Year Low

-$397.40 K

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
VTGN previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 13, 2025
VTGN next earnings announcement is scheduled for Feb 13, 2025

OtherVTGNcash flowmetrics:

Quarterly CFI

-$7.79 M
VTGN quarterly cash flow from investing activities is -$7.79 million

Quarterly CFO

-$10.89 M
VTGN quarterly cash flow from operations is -$10.89 million

Quarterly FCF

-$10.95 M
VTGN quarterly free cash flow is -$10.95 million

Quarterly CAPEX

$61.00 K
VTGN quarterly capital expenditures is $61.00 thousand

TTM CFF

$93.44 M
-$34.18 M-26.78%

September 30, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

0%

3-Year Change

0%

5-Year Change

0%

VTGN TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

81.29%
VTGN TTM cash flow from financing activities is higher than 81.29% of companies in Healthcare sector

High & Low

All-time High

$128.40 M
VTGN TTM cash flow from financing activities is currently -27.23% below its historical high of $128.40 million

3-Year Low

-$1.04 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
VTGN previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 13, 2025
VTGN next earnings announcement is scheduled for Feb 13, 2025

OtherVTGNcash flowmetrics:

TTM CFI

-$13.31 M
VTGN TTM cash flow from investing activities is -$13.31 million

TTM CFO

-$33.49 M
VTGN TTM cash flow from operations is -$33.49 million

TTM FCF

-$33.65 M
VTGN TTM free cash flow is -$33.65 million

TTM CAPEX

$164.00 K
VTGN TTM capital expenditures is $164.00 thousand

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

VTGN Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+10000.0%0.0%0.0%
3 y3 years+12.5%0.0%0.0%
5 y5 years+637.0%0.0%0.0%

VTGN Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high>+9999.0%-100.0%+100.0%-27.2%+9075.9%
5 y5-yearat high>+9999.0%-100.0%+100.0%-27.2%+9075.9%
alltimeall timeat high>+9999.0%-100.0%+100.0%-27.2%+9075.9%

VistaGen Therapeutics Cash From Financing History

DateAnnualQuarterlyTTM
Sep 2024
-
$0.00(-100.0%)
$93.44 M(-26.8%)
Jun 2024
-
$88.00 K(-152.4%)
$127.61 M(-0.6%)
Mar 2024
$128.40 M(<-9900.0%)
-$167.80 K(-100.2%)
$128.40 M(+0.2%)
Dec 2023
-
$93.52 M(+173.6%)
$128.17 M(+273.1%)
Sep 2023
-
$34.18 M(+3805.8%)
$34.35 M(<-9900.0%)
Jun 2023
-
$875.00 K(-320.2%)
-$160.50 K(-84.6%)
Mar 2023
-$1.04 M(-109.9%)
-$397.40 K(+30.7%)
-$1.04 M(+67.9%)
Dec 2022
-
-$304.10 K(-9.0%)
-$619.90 K(-134.4%)
Sep 2022
-
-$334.00 K(+5972.7%)
$1.80 M(-81.0%)
Jun 2022
-
-$5500.00(-123.2%)
$9.49 M(-9.5%)
Mar 2022
$10.48 M(-90.8%)
$23.70 K(-98.9%)
$10.48 M(-27.9%)
Dec 2021
-
$2.12 M(-71.2%)
$14.54 M(-86.3%)
Sep 2021
-
$7.35 M(+641.4%)
$106.50 M(-5.0%)
Jun 2021
-
$991.40 K(-75.7%)
$112.10 M(-1.8%)
Mar 2021
$114.10 M(+2744.2%)
$4.08 M(-95.7%)
$114.10 M(+1.1%)
Dec 2020
-
$94.07 M(+626.5%)
$112.89 M(+462.0%)
Sep 2020
-
$12.95 M(+332.0%)
$20.09 M(+184.9%)
Jun 2020
-
$3.00 M(+4.4%)
$7.05 M(+75.8%)
Mar 2020
$4.01 M(-77.0%)
$2.87 M(+126.0%)
$4.01 M(-65.2%)
Dec 2019
-
$1.27 M(-1545.4%)
$11.52 M(-8.6%)
Sep 2019
-
-$87.90 K(+110.3%)
$12.61 M(-27.4%)
Jun 2019
-
-$41.80 K(-100.4%)
$17.36 M(-0.4%)
Mar 2019
$17.42 M(+5.5%)
$10.38 M(+339.5%)
$17.42 M(+149.0%)
Dec 2018
-
$2.36 M(-49.4%)
$7.00 M(-61.9%)
Sep 2018
-
$4.66 M(>+9900.0%)
$18.35 M(+16.9%)
Jun 2018
-
$23.60 K(-147.3%)
$15.70 M(-4.9%)
Mar 2018
$16.52 M(+65.3%)
-$49.90 K(-100.4%)
$16.52 M(-0.7%)
Dec 2017
-
$13.71 M(+581.0%)
$16.64 M(+430.0%)
Sep 2017
-
$2.01 M(+139.4%)
$3.14 M(+187.8%)
Jun 2017
-
$841.00 K(+1063.2%)
$1.09 M(-89.1%)
Mar 2017
$9.99 M(+92.4%)
$72.30 K(-65.9%)
$9.99 M(-5.0%)
Dec 2016
-
$212.30 K(-706.6%)
$10.52 M(-11.9%)
Sep 2016
-
-$35.00 K(-100.4%)
$11.95 M(-15.0%)
Jun 2016
-
$9.74 M(+1520.3%)
$14.06 M(+170.8%)
DateAnnualQuarterlyTTM
Mar 2016
$5.19 M(+82.9%)
$601.40 K(-63.3%)
$5.19 M(-6.3%)
Dec 2015
-
$1.64 M(-21.2%)
$5.54 M(+30.2%)
Sep 2015
-
$2.08 M(+137.8%)
$4.26 M(+85.1%)
Jun 2015
-
$874.30 K(-8.1%)
$2.30 M(-19.0%)
Mar 2015
$2.84 M(+89.6%)
$951.30 K(+168.6%)
$2.84 M(+21.6%)
Dec 2014
-
$354.20 K(+193.0%)
$2.33 M(+0.9%)
Sep 2014
-
$120.90 K(-91.4%)
$2.31 M(-14.9%)
Jun 2014
-
$1.41 M(+216.4%)
$2.72 M(+81.4%)
Mar 2014
$1.50 M(-64.0%)
$446.40 K(+34.2%)
$1.50 M(-43.3%)
Dec 2013
-
$332.60 K(-36.7%)
$2.64 M(-22.6%)
Sep 2013
-
$525.40 K(+172.1%)
$3.41 M(-16.8%)
Jun 2013
-
$193.10 K(-87.8%)
$4.10 M(-1.3%)
Mar 2013
$4.16 M(+17.4%)
$1.59 M(+43.8%)
$4.16 M(+29.1%)
Dec 2012
-
$1.10 M(-9.2%)
$3.22 M(-1.0%)
Sep 2012
-
$1.22 M(+392.5%)
$3.25 M(+71.3%)
Jun 2012
-
$246.90 K(-62.1%)
$1.90 M(-46.4%)
Mar 2012
$3.54 M(>+9900.0%)
$652.20 K(-42.6%)
$3.54 M(+22.3%)
Dec 2011
-
$1.14 M(-926.2%)
$2.89 M(+64.5%)
Sep 2011
-
-$137.50 K(-107.3%)
$1.76 M(-7.3%)
Jun 2011
-
$1.89 M(>+9900.0%)
$1.90 M(>+9900.0%)
Mar 2011
-
$6000.00(+275.0%)
$11.10 K(+37.0%)
Dec 2010
$8100.00(+440.0%)
$1600.00(+220.0%)
$8100.00(+24.6%)
Sep 2010
-
$500.00(-83.3%)
$6500.00(-13.3%)
Jun 2010
-
$3000.00(0.0%)
$7500.00(+66.7%)
Mar 2010
-
$3000.00(>+9900.0%)
$4500.00(+200.0%)
Dec 2009
$1500.00(-96.0%)
$0.00(-100.0%)
$1500.00(-96.1%)
Sep 2009
-
$1500.00(>+9900.0%)
$38.40 K(+4.1%)
Jun 2009
-
$0.00(0.0%)
$36.90 K(0.0%)
Mar 2009
-
$0.00(-100.0%)
$36.90 K(-1.3%)
Dec 2008
$37.40 K
$36.90 K(>+9900.0%)
$37.40 K(+7380.0%)
Sep 2008
-
$0.00(0.0%)
$500.00(0.0%)
Jun 2008
-
$0.00(-100.0%)
$500.00(0.0%)
Mar 2008
-
$500.00(>+9900.0%)
$500.00(>+9900.0%)
Mar 2007
-
$0.00
$0.00

FAQ

  • What is VistaGen Therapeutics annual cash flow from financing activities?
  • What is the all time high annual CFF for VistaGen Therapeutics?
  • What is VistaGen Therapeutics annual CFF year-on-year change?
  • What is VistaGen Therapeutics quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for VistaGen Therapeutics?
  • What is VistaGen Therapeutics quarterly CFF year-on-year change?
  • What is VistaGen Therapeutics TTM cash flow from financing activities?
  • What is the all time high TTM CFF for VistaGen Therapeutics?
  • What is VistaGen Therapeutics TTM CFF year-on-year change?

What is VistaGen Therapeutics annual cash flow from financing activities?

The current annual CFF of VTGN is $128.40 M

What is the all time high annual CFF for VistaGen Therapeutics?

VistaGen Therapeutics all-time high annual cash flow from financing activities is $128.40 M

What is VistaGen Therapeutics annual CFF year-on-year change?

Over the past year, VTGN annual cash flow from financing activities has changed by +$129.44 M (+12434.49%)

What is VistaGen Therapeutics quarterly cash flow from financing activities?

The current quarterly CFF of VTGN is $0.00

What is the all time high quarterly CFF for VistaGen Therapeutics?

VistaGen Therapeutics all-time high quarterly cash flow from financing activities is $94.07 M

What is VistaGen Therapeutics quarterly CFF year-on-year change?

Over the past year, VTGN quarterly cash flow from financing activities has changed by $0.00 (0.00%)

What is VistaGen Therapeutics TTM cash flow from financing activities?

The current TTM CFF of VTGN is $93.44 M

What is the all time high TTM CFF for VistaGen Therapeutics?

VistaGen Therapeutics all-time high TTM cash flow from financing activities is $128.40 M

What is VistaGen Therapeutics TTM CFF year-on-year change?

Over the past year, VTGN TTM cash flow from financing activities has changed by $0.00 (0.00%)